SELE and acute myeloid leukemia: E-selectin can be inhibited by the small-molecule antagonist Uproleselan (GMI-1271), which favors the reduction of cell survival and the increase of chemosensitivity, showing a contraction in the leukemic burden in xenograft AML models treated with a combination of chemotherapy and this E-selectin antagonist [35].